Stockreport

One-Year Results from Positive Phase 3 EYLEA Trial in Diabetic Retinopathy Presented at Angiogenesis Symposium

Regeneron Pharmaceuticals, Inc.  (REGN) 
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
PDF TARRYTOWN, N.Y., Feb. 9, 2019 /PRNewswire/ -- Trial showed that early intervention with EYLEA improved diabetic retinopathy severity and prevented serious vision-threa [Read more]